Initial primary extranodal lymphoma locations according to stage
| Extranodal site . | All patients, N (%) . | Stage I, N (%) . | Stage II, N (%) . | Stage IV, N (%) . |
|---|---|---|---|---|
| Total | 180 (100) | 115 (100) | 16 (100) | 49 (100) |
| Skin | 22 (12) | 18 (16) | 0 (0) | 4 (8) |
| Conjunctiva | 18 (10) | 18 (16) | 0 (0) | 0 (0) |
| Orbit | 13 (7) | 9 (8) | 0 (0) | 4 (8) |
| Salivary glands | 46 (26) | 39 (34) | 3 (19) | 4 (8) |
| Thyroid | 10 (6) | 6 (5) | 4 (25) | 0 (0) |
| Upper airways (+Waldeyer ring) | 12 (7) | 6 (5) | 2 (12) | 4 (8) |
| Lung | 15 (8) | 9 (8) | 3 (19) | 3 (6) |
| Breast | 3 (2) | 3 (3) | 0 (0) | 0 (0) |
| Liver | 6 (3) | 0 (0) | 0 (0) | 6 (12) |
| Bowel | 9 (5) | 5 (4) | 4 (25) | 0 (0) |
| Urinary tract | 2 (1) | 2 (2) | 0 (0) | 0 (0) |
| Multiple mucosal sites | 24 (13) | 0 (0) | 0 (0) | 24 (49) |
| Extranodal site . | All patients, N (%) . | Stage I, N (%) . | Stage II, N (%) . | Stage IV, N (%) . |
|---|---|---|---|---|
| Total | 180 (100) | 115 (100) | 16 (100) | 49 (100) |
| Skin | 22 (12) | 18 (16) | 0 (0) | 4 (8) |
| Conjunctiva | 18 (10) | 18 (16) | 0 (0) | 0 (0) |
| Orbit | 13 (7) | 9 (8) | 0 (0) | 4 (8) |
| Salivary glands | 46 (26) | 39 (34) | 3 (19) | 4 (8) |
| Thyroid | 10 (6) | 6 (5) | 4 (25) | 0 (0) |
| Upper airways (+Waldeyer ring) | 12 (7) | 6 (5) | 2 (12) | 4 (8) |
| Lung | 15 (8) | 9 (8) | 3 (19) | 3 (6) |
| Breast | 3 (2) | 3 (3) | 0 (0) | 0 (0) |
| Liver | 6 (3) | 0 (0) | 0 (0) | 6 (12) |
| Bowel | 9 (5) | 5 (4) | 4 (25) | 0 (0) |
| Urinary tract | 2 (1) | 2 (2) | 0 (0) | 0 (0) |
| Multiple mucosal sites | 24 (13) | 0 (0) | 0 (0) | 24 (49) |